NCT01436149CompletedPhase 3
The SPD489-322 Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Inadequate Response to Prospective Treatment With an Antidepressant
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Shire
- Enrollment
- 1,262
- Locations
- 85
- Primary Endpoint
- Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at up to 8 Weeks
Study Overview
Brief Summary
This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms. Eligible patients will remain on their antidepressant but will be randomized to either receive supplemental SPD489 or placebo (i.e. sugar pill). The purpose of this study is to help answer the following questions:
- How safe is SPD489 for the supplemental treatment of depression and what are the side effects that might be related to it?
- Can supplemental SPD489 help patients who still have residual depression symptoms while taking an antidepressant?
- How much SPD489 should be given to patients with depression who are also taking an antidepressant?
- How does SPD489 compare to placebo in depressed patients who are also taking an antidepressant?
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Subject is able to provide written, personally signed, and dated informed consent to participate in the study.
- •Subject is between 18 and 65 years of age.
- •Subject has a primary diagnosis of non-psychotic MDD (single or recurrent).
- •Subject has a MADRS total score
- •Subject who is female, must have a negative serum beta human chorionic gonadotropin (HCG) pregnancy test and a negative urine pregnancy test at the and agrees to comply with any applicable contraceptive requirements of the protocol.
- •Subject is able to swallow a capsule.
Exclusion Criteria
- •Subject whose current episode of MDD has not responded to an adequate treatment regimen with 2 or more approved single antidepressant agents.
- •Subject who has a lifetime history of treatment resistant depression.
- •Subject has a current co-morbid psychiatric disorder. Excluded are: any significant Axis II disorder (including borderline personality disorder), any bipolar disorder, any current or lifetime psychosis, post traumatic stress disorder, obsessive compulsive disorder, any pervasive development disorder, anorexia nervosa and bulimia nervosa.
- •Subject has been hospitalized (within the last 12 months) for their current MDD episode.
- •Subject has a current or lifetime history of attention-deficit/hyperactivity disorder (ADHD).
- •Subject has a first degree relative that has been diagnosed with bipolar I disorder.
- •Subject has a recent history (within the last 6 months) of suspected substance abuse or dependence disorder
- •Subject is considered a suicide risk in the opinion of the Investigator, has previously made a suicide attempt within the past 3 years, or is currently demonstrating active suicidal ideation.
- •Subject has a concurrent chronic or acute illness or unstable medical condition.
- •Subject has a history of seizures (other than infantile febrile seizures), any tic disorder, or a current diagnosis and/or a known family history of Tourette's Disorder, serious neurological disease, history of significant head trauma, dementia, cerebrovascular disease, Parkinson's disease, or intracranial lesions.
- •Subject has known history of symptomatic cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems.
- •Subject has a history of thyroid disorder that has not been stabilized on thyroid medication or treatment within 3 months prior to the Screening Visit.
- •Subject has a known family history of sudden cardiac death or ventricular arrhythmia.
- •Subject has glaucoma.
- •Subject has a history of moderate to severe hypertension.
- •Current use of any other medications (including over-the-counter [OTC], herbal or homeopathic preparations) that have central nervous system effects.
- •Subject has had electroconvulsive therapy (ECT) for the current depressive episode 3 months prior.
- •The subject has a known or suspected intolerance, hypersensitivity, or contraindications to their assigned antidepressant treatments (escitalopram oxalate, sertraline HCl, venlafaxine HCl extended release, or duloxetine HCl).
- •Subject has a positive urine drug result.
- •Subject has a body mass index (BMI) of <18.5 or >
- •Subject is female and is pregnant or nursing.
Arms & Interventions
Antidepressant + SPD489
Experimental
Intervention: SPD489 (Lisdexamfetamine dimesylate ) (Drug)
Antidepressant + Placebo
Placebo Comparator
Intervention: Placebo (Drug)
Outcomes
Primary Outcomes
Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at up to 8 Weeks
Time Frame: 8 weeks
MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression.
Secondary Outcomes
- Mean Change From Baseline in the Short Form-12 Health Survey V2 (SF-12V2)(up to 8 weeks)
- Percentage of Participants Achieving a 25% Response on the MADRS(up to 8 weeks)
- Percentage of Participants Achieving a 50% Response on the MADRS(up to 8 weeks)
- Percentage of Participants Achieving Remission on the MADRS(up to 8 weeks)
- Change From Baseline in Sheehan Disability Scale (SDS) Total Score at up to 8 Weeks(8 weeks)
- Mean Change From Baseline Over Time in MADRS Total Score(Baseline and up to 8 weeks)
- Mean Change From Baseline in the Quick Inventory of Depressive Symptomatology - Self Report (QIDS SR)(up to 8 weeks)
- Mean Change From Baseline in the Quality of Life Enjoyment Satisfaction Questionnaire Short Form (Q-LES-Q-SF)(up to 8 weeks)
- Clinical Global Impressions - Global Improvement (CGI-I)(up to 8 weeks)
- Columbia Suicide Severity Rating Scale (C-SSRS)(up to 8 weeks)
- Amphetamine Cessation Symptom Assessment (ACSA)(up to 8 weeks)
Investigators
Study Sites (85)
Loading locations...
Similar Trials
Completed
Phase 3
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive DisorderMajor Depressive DisorderNCT01436162Shire1,105
Completed
Phase 2
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive DisorderMajor Depressive DisorderNCT01435759Shire1,197
Completed
Phase 2
A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive MedicineDepressive Disorder, MajorNCT06280235Boehringer Ingelheim84
Terminated
Phase 3
SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension StudyMajor Depressive DisorderNCT01436175Shire1,570
Completed
Phase 2
A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With DepressionDepressive Disorder, MajorNCT04521478Boehringer Ingelheim389